Dr. Barry Holtz, President of G-Con, is a recognized international expert on design and construction of pharmaceutical facilities. David Haselwood, an experienced life science entrepreneur, investor and operator, heads up business operations for G-Con.Barry Holtz appears to be the proprietor of Holtz BioPharma Consulting
Dr. Holtz has 30 years of experience in the development of bioproducts and biopharmaceuticals. Serving 15 years as Senior Vice President for Large Scale Biology Corporation, Dr. Holtz was responsible for the product development, clinical development and manufacturing compliance of the company's proprietary therapeutics portfolio. These projects included leading development and manufacturing teams that successfully brought a recombinant, plant-made, patient specific vaccine, for treatment of indolent Non-Hodgkin's lymphoma,from the bench to human clinical trials. Dr. Holtz was also responsible for the design, construction and commissioning of the LSBC biopharmaceutical production facility in Owensboro, Kentucky. Dr. Holtz has also designed and built two other bioproducts facilities for other clients. Recent efforts have included design and construction of cancer vaccine facilities, implementing proteogenomics into vaccine manufacture and international development of biotechnology development in resource challenged countries.Pubmed finds some papers that could be from Holtz's graduate and postdoctoral work. More relevant to the NCTM is this paper from Large Scale Biology Corporation describing production of anticancer vaccines using Tobacco Mosaic Virus vectors in plants. This has been used by Bayer, in collaboration with Icon Genetics (a competitor of LSBC?), which is also listed under the projects page at G-Con.
Prior to Large Scale Biology, Dr. Holtz was the founder and President of Holtz Bio-Engineering. Over its' nine year history, the company was involved in the development of bioreactor based processes for the biotechnology sector and developed a proprietary line of bioreactors and distributed logic control systems for cell culture. Holtz Bio-Engineering was merged into Large Scale Biology in 1989.
Dr. Holtz has held research management positions at Foremost-Mckesson and was on the faculty of Ohio State University. He received his Ph.D. at Pennsylvania State University and was an NSF Postdoctoral Fellow at Scripps Institution of Oceanography. Dr. Holtz has been awarded 22 US patents and has published over 50 scientific papers. Dr. Holtz was awarded the Pennsylvania State University, Outstanding Alumni Award in 2003.
Large Scale Biology Corporation appears to have published the paper a couple of years after going bankrupt.
David Haselwood is a 2004 Berkeley MPH/MBA who has also been with Gradalis since 2008. From 2004-2006, he worked at Burrill & Company, a venture capital firm focusing on biotech.